Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

288P - Real-world outcomes and safety of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients: A prospective cohort study

Date

16 Sep 2021

Session

ePoster Display

Topics

Cytotoxic Therapy;  Clinical Research

Tumour Site

Breast Cancer

Presenters

Ting Luo

Citation

Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689

Authors

T. Luo1, Q. Zhang1, P. He1, X. Zhong1, X. Yan1, T. Tian1, J. Huang2, Z. Zhang3, H. Zheng1

Author affiliations

  • 1 Department Of Head, Neck And Mammary Gland Oncology, Cancer Center, West China Hospital of Sichuan University, 610041 - Chengdu/CN
  • 2 Department Of Radiology, West China Hospital of Sichuan University, 610041 - Chengdu/CN
  • 3 Department Of Pathology, West China Hospital of Sichuan University, 610041 - Chengdu/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 288P

Background

Pyrotinib, a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor, shows promising antitumor activity and acceptable tolerability in phase II and phase III randomized clinical trials. However, the real-world data of pyrotinib have been rarely reported. Here, we assessed the treatment outcomes of pyrotinib in real-world practice in patients with HER2-positive MBC patients.

Methods

This was a China-based, prospective, real-world, observational cohort study. HER-2 Positive MBC Patients treated with pyrobitinib were indentified from the Breast Cancer Information Management System between 2017/06 and 2020/09. Treatment outcomes assessment included provider-reported objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). The responses were determined by RECIST 1.1, and adverse events were assessed using patients and clinical records.

Results

113 pyrotinib-treated patients with an average age of 51 years enrolled in the study. 64 (56.6%) patients had 2 or more sites of metastasis. Distant metastases were in lungs, livers, brains and bones (45.1%, 38.9%, 26.6% and 8.0%, respectively). Pyritinib was used as first-line therapy in 20 (17.7%) patients, second-line in 61 (54.0%) patients, and as third-line and beyond in 30 (28.3%) patients. 102 (90.3%) patients had used anti-HER2 therapy before. By the cut-off day therapy was continued in 47 (41.2%). Complete response, partial response and stable disease were observed in 9 (8.0%), 66 (58.4%), and 17 (15.0%) patients, respectively; progressive disease was recorded in 20 (17.7%) patients. The median PFS was 14.1 months. The median OS was 34.1 months after a median follow up of 17.2 months. Among the patients with brain metastases, the median PFS and OS was 15.2 and 19.8 months, respectively. The most common adverse events of any grade were diarrhea (87.6%), vomiting (31.9%), palmar-plantar erythrodysesthesia syndrome (26.6%).

Conclusions

Compared with phase II and phase III clinical trails of pyrotinib, our real-world data showed simiar clinical effectiveness in HER-2 positive MBC patients and, in particular, improved outcomes in patients with brain metastasis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.